AstraZeneca plc Or Diageo plc: Which Stock Is Better For Income and Growth?

A look at two non-cyclical dividend stocks: AstraZeneca plc (LON:AZN) and Diageo plc (LON:DGE) – focussing on their recent trading conditions, near term earnings outlook and valuations.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It may seem strange to compare Astrazeneca (LSE: AZN) with Diageo (LSE: DGE) — the two stocks do not even belong to the same sector. However, there are quite a few similarities between them — both stocks are low-beta blue-chip companies that have been seeing earnings growth falter in recent years.

Historically, both stocks have delivered a reliable combination of income and capital growth, too. Astrazeneca has delivered a total return (that is, the rate of return with dividends being reinvested in the company) of 88% over the past five years, while Diageo has managed 49%.

Remember, though, past performance is no guarantee of future results.

Recent trading conditions

Diageo, the £47bn alcoholic beverages company, reported its interim earnings today and said that underlying EPS fell 4% to 51.3p in the six months to December 31. Although the company managed to generate a 1.8% organic growth in revenues, adverse currency movements and the disposal of non-core assets led operating profits to fall by £156m, to £1,717m.

Overall, trading conditions are challenging. The impact of adverse currency movements is largely out of the management’s control, but the company has been doing well at what it can control. It has delivered continued margin improvement and steady volumes growth. And, despite the earnings trend, free cash flow is growing, allowing Diageo to increase its interim dividend by 5% to 22.6p per share.

Astrazeneca’s earnings trend in recent years is in much worse shape. Underlying EPS has fallen by an annualised rate of 16.2% over the last three years, compared to 2.0% for Diageo, as the pharma company’s patent protection has expired on some of its “blockbuster” drugs. Ongoing launches on new treatments are just beginning to offset the trend in declining revenues, but have yet to have the same impact on earnings.

Looking forward, though, Astrazeneca’s revitalised portfolio of portfolio of investigational therapies should allow the company to emerge from its earnings slump. The pharmaceutical company has some 131 projects in our pipeline, with 15 in the late-stage of development.

We will know more about Astrazeneca’s trading performance when the company reports its full-year earnings on February 4.

Valuations

  Astrazeneca Diageo
Forward P/E 15.8 21.3
Prospective Dividend Yield 4.4% 3.0%
Adjusted Payout Ratio (2015) 64% 66%
2-year Forecast Annualised EPS Growth -6.0% 4.3%

Both companies have forward P/E ratios slightly ahead of the FTSE 100 average, but both also offer reasonably high levels of income with a dividend payout ratio of around two-thirds of underlying earnings.

Based on these valuation ratios, Astrazeneca seems to be the cheaper of the two. But, it is important to note that the company has kept its dividend frozen at $2.80 a year since 2011, and analysts expect it will remain frozen for at least another two years. With earnings forecast to decline by an annualised rate of 6.0% over the next two years, the pharmaceutical company is not exactly in a strong position to grow its dividend. Its dividend payout ratio is expected to climb from 64% in 2015, to around 74% by the end of 2017.

By contrast, Diageo’s growth prospects are more attractive. Its earnings outlook is brighter, with earnings set to grow by an annualised rate of 4.3% over the next two years. This should allow the company to maintain its a progressive dividend policy. So, whilst growth comes at a price, for me, it seems to be worth it.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »